AR013506A1 - Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida - Google Patents

Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida

Info

Publication number
AR013506A1
AR013506A1 ARP980104682A ARP980104682A AR013506A1 AR 013506 A1 AR013506 A1 AR 013506A1 AR P980104682 A ARP980104682 A AR P980104682A AR P980104682 A ARP980104682 A AR P980104682A AR 013506 A1 AR013506 A1 AR 013506A1
Authority
AR
Argentina
Prior art keywords
salt
budesonide
solvate
manufacture
treatment
Prior art date
Application number
ARP980104682A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR013506(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR013506A1 publication Critical patent/AR013506A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP980104682A 1997-09-19 1998-09-18 Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida AR013506A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use

Publications (1)

Publication Number Publication Date
AR013506A1 true AR013506A1 (es) 2000-12-27

Family

ID=20408325

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104682A AR013506A1 (es) 1997-09-19 1998-09-18 Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida

Country Status (38)

Country Link
US (2) US7897646B2 (en:Method)
EP (2) EP1210943B1 (en:Method)
JP (1) JP2001517630A (en:Method)
KR (1) KR20010024140A (en:Method)
CN (1) CN1149998C (en:Method)
AR (1) AR013506A1 (en:Method)
AT (2) ATE329599T1 (en:Method)
AU (1) AU757235B2 (en:Method)
BR (1) BR9812325A (en:Method)
CA (1) CA2302700C (en:Method)
CY (1) CY1106156T1 (en:Method)
CZ (1) CZ295250B6 (en:Method)
DE (2) DE69807239T2 (en:Method)
DK (2) DK1014993T3 (en:Method)
EE (1) EE04297B1 (en:Method)
ES (2) ES2266322T3 (en:Method)
HK (1) HK1045812B (en:Method)
HU (1) HUP0003848A2 (en:Method)
ID (1) ID24838A (en:Method)
IL (1) IL134773A (en:Method)
IN (1) IN190791B (en:Method)
IS (1) IS2715B (en:Method)
MX (1) MXPA00002615A (en:Method)
MY (1) MY127812A (en:Method)
NO (1) NO327176B1 (en:Method)
NZ (1) NZ503173A (en:Method)
PL (1) PL190782B1 (en:Method)
PT (2) PT1014993E (en:Method)
RU (1) RU2199322C2 (en:Method)
SA (1) SA98190773B1 (en:Method)
SE (1) SE9703407D0 (en:Method)
SI (2) SI1014993T1 (en:Method)
SK (1) SK285330B6 (en:Method)
TR (1) TR200000726T2 (en:Method)
TW (1) TW546140B (en:Method)
UA (1) UA72446C2 (en:Method)
WO (1) WO1999015182A1 (en:Method)
ZA (1) ZA988516B (en:Method)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
ATE233550T1 (de) * 1998-11-13 2003-03-15 Jago Res Ag Trockenpulver zur inhalation
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
MXPA03007017A (es) * 2001-02-06 2004-09-13 Innovata Biomed Ltd Medicamentos.
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
JP4778053B2 (ja) 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
JP2009519970A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経口投与用製薬剤形の製造方法
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
WO2008048770A1 (en) * 2006-10-17 2008-04-24 Lipothera, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
ES2592536T3 (es) 2009-05-29 2016-11-30 Pearl Therapeutics, Inc. Composiciones para administración a los pulmones de antagonistas muscarínicos de acción prolongada y agonistas de los receptores beta-2-adrenérgicos de acción prolongada y métodos y sistemas asociados
US20110132355A1 (en) * 2009-06-09 2011-06-09 William Gerhart Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
BR112012017556A2 (pt) * 2010-01-15 2016-08-16 Lithera Inc formulações de torta liofilizada
EP2646012A4 (en) 2010-11-24 2014-12-10 Neothetics Inc MONOTHERAPEUTIC FORMULATIONS OF SELECTIVE, LIPOPHILIC AND PROLONGED BETA AGONISTS AND METHODS OF COSMETIC TREATMENT OF SILHOUETTE ADPOSITY AND REINFORCEMENT
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
US11559505B2 (en) 2015-12-04 2023-01-24 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CN112997256A (zh) 2018-06-14 2021-06-18 阿斯利康(英国)有限公司 使用皮质类固醇医药组合物治疗和预防哮喘症状的方法
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2021076701A1 (en) 2019-10-17 2021-04-22 Trustees Of Boston University Methods and compositions relating to lung function

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2235626B (en) 1989-09-08 1994-02-09 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
SK282826B6 (sk) * 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
EP0613371B1 (en) 1991-12-18 2002-03-06 AstraZeneca AB New combination of formoterol and budesonide
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9519692D0 (en) * 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
IL124522A0 (en) * 1995-11-24 1998-12-06 Smithkline Beecham Spa Quinoline derivatives
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
BR9810452A (pt) 1997-06-27 2000-09-05 Astra Ab Nova combinação de medicamentos contra asma
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
CN1149998C (zh) 2004-05-19
PL190782B1 (pl) 2006-01-31
EE04297B1 (et) 2004-06-15
US8461211B2 (en) 2013-06-11
DE69807239T2 (de) 2003-04-10
DE69834955T2 (de) 2007-01-25
KR20010024140A (ko) 2001-03-26
BR9812325A (pt) 2000-09-05
DK1014993T3 (da) 2002-11-11
HK1045812B (en) 2006-12-22
EP1210943B1 (en) 2006-06-14
PT1014993E (pt) 2002-12-31
US7897646B2 (en) 2011-03-01
JP2001517630A (ja) 2001-10-09
ZA988516B (en) 1999-03-19
IL134773A (en) 2005-03-20
EE200000145A (et) 2001-02-15
US20020042404A1 (en) 2002-04-11
MY127812A (en) 2006-12-29
NO20001401L (no) 2000-03-17
PT1210943E (pt) 2006-09-29
DE69834955D1 (de) 2006-07-27
IS2715B (is) 2011-02-15
IS5407A (is) 2000-03-15
EP1014993A1 (en) 2000-07-05
ES2266322T3 (es) 2007-03-01
SA98190773B1 (ar) 2006-10-02
SE9703407D0 (sv) 1997-09-19
US20110097282A1 (en) 2011-04-28
HUP0003848A2 (hu) 2001-08-28
CN1271287A (zh) 2000-10-25
SI1210943T1 (sl) 2006-10-31
TW546140B (en) 2003-08-11
IN190791B (en:Method) 2003-08-23
NZ503173A (en) 2001-08-31
DK1210943T3 (da) 2006-09-18
IL134773A0 (en) 2001-04-30
ID24838A (id) 2000-08-24
CZ295250B6 (cs) 2005-06-15
CA2302700C (en) 2010-11-23
SK285330B6 (sk) 2006-11-03
EP1210943A1 (en) 2002-06-05
NO327176B1 (no) 2009-05-04
CY1106156T1 (el) 2011-06-08
SK3892000A3 (en) 2000-12-11
EP1014993B1 (en) 2002-08-14
CZ2000950A3 (cs) 2000-06-14
UA72446C2 (uk) 2005-03-15
SI1014993T1 (en) 2003-02-28
ATE222106T1 (de) 2002-08-15
ES2182357T3 (es) 2003-03-01
RU2199322C2 (ru) 2003-02-27
US20060189587A9 (en) 2006-08-24
CA2302700A1 (en) 1999-04-01
HK1045812A1 (en) 2002-12-13
AU757235B2 (en) 2003-02-06
TR200000726T2 (tr) 2000-09-21
NO20001401D0 (no) 2000-03-17
WO1999015182A1 (en) 1999-04-01
PL339295A1 (en) 2000-12-04
AU9192898A (en) 1999-04-12
MXPA00002615A (es) 2002-04-24
ATE329599T1 (de) 2006-07-15
DE69807239D1 (de) 2002-09-19

Similar Documents

Publication Publication Date Title
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
BG102689A (bg) Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения
ES2178943A1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
BR0207024A (pt) Medicamento com ação inicial rápida para o tratamento de disfunção sexual
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
ATE308317T1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
AR013614A1 (es) Nueva composicion que comprende una combinacion de esteroides, un kit que la contiene, el uso de la misma, el uso de dicho kit de formoterol y debudesonida en la fabricacion de un medicamento
ATE398999T1 (de) Aerosol-formulierungen von formoterol und mometason
AR033688A1 (es) Composicion parenteral reconstituible
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
JP2002528502A5 (en:Method)
ES2171440T3 (es) Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal.
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
BR0315316A (pt) Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
ES2099021B1 (es) Composicion farmaceutica que tiene actividad analgesica.
PE20020387A1 (es) Uso de una combinacion de salmeterol y fluticasona
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure